Filtered By:
Cancer: Carcinoma
Drug: Fortamet
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 18 results found since Jan 2013.
Metformin Promotes 2-Deoxy-2- 18 FFluoro-D-Glucose Uptake in Hepatocellular Carcinoma Cells Through FoxO1-Mediated Downregulation of Glucose-6-Phosphatase
ConclusionsWe propose that treatment of HCC cells with Met may be a useful strategy for improving the efficacy of [18F]FDG as a tracer for PET/CT imaging of HCC tumors in patients.
Source: Molecular Imaging and Biology - December 18, 2017 Category: Molecular Biology Source Type: research
Metformin inhibits tumorigenesis in HBV ‐induced hepatocellular carcinoma by suppressing HULC overexpression caused by HBX
Conclusion: This study indicated that metformin imposed inhibitory effect on the HBV‐associated HCC by negatively regulating the HULC /p18/miR‐200a/ZEB1 signaling pathway. This article is protected by copyright. All rights reserved
Source: Journal of Cellular Biochemistry - December 12, 2017 Category: Biochemistry Authors: Zhen Jiang, Haichao Liu Tags: Article Source Type: research
Reversal of multidrug resistance of hepatocellular carcinoma cells by metformin through inhibiting NF- κB gene transcription.
CONCLUSION: Metformin via silencing NF-κB signaling could effectively reverse MDR of HCC cells by down-regulating MDR1/P-gp expression.
PMID: 27621764 [PubMed]
Source: World Journal of Hepatology - September 15, 2016 Category: Gastroenterology Tags: World J Hepatol Source Type: research
